Growth Metrics

Quest Diagnostics (DGX) Net Income towards Common Stockholders (2016 - 2026)

Quest Diagnostics has reported Net Income towards Common Stockholders over the past 18 years, most recently at -$40.0 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 121.74% to -$40.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $637.0 million through Mar 2026, down 18.33% year-over-year, with the annual reading at $968.0 million for FY2025, 11.65% up from the prior year.
  • Net Income towards Common Stockholders was -$40.0 million for Q1 2026 at Quest Diagnostics, down from $213.0 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $304.0 million in Q1 2022 and troughed at -$40.0 million in Q1 2026.
  • The 5-year median for Net Income towards Common Stockholders is $199.0 million (2024), against an average of $184.3 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 113.16% in 2023 and later crashed 121.74% in 2026.
  • Tracing DGX's Net Income towards Common Stockholders over 5 years: stood at $76.0 million in 2022, then soared by 113.16% to $162.0 million in 2023, then grew by 20.99% to $196.0 million in 2024, then rose by 8.67% to $213.0 million in 2025, then crashed by 118.78% to -$40.0 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$40.0 million, $213.0 million, and $214.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.